Form 8-K - Current report:
SEC Accession No. 0001193125-26-269387
Filing Date
2026-06-12
Accepted
2026-06-12 16:06:06
Documents
9
Period of Report
2026-06-11
Items
Item 5.07: Submission of Matters to a Vote of Security Holders

Document Format Files

Seq Description Document Type Size
1 8-K janx-20260611.htm   iXBRL 8-K 67398
  Complete submission text file 0001193125-26-269387.txt   176914

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT janx-20260611.xsd EX-101.SCH 27197
12 EXTRACTED XBRL INSTANCE DOCUMENT janx-20260611_htm.xml XML 4721
Mailing Address 10955 VISTA SORRENTO PARKWAY SUITE 200 SAN DIEGO CA 92130
Business Address 10955 VISTA SORRENTO PARKWAY SUITE 200 SAN DIEGO CA 92130 (858) 751-4493
Janux Therapeutics, Inc. (Filer) CIK: 0001817713 (see all company filings)

EIN.: 822289112 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40475 | Film No.: 261086623
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)